Venous thromboembolism (VTE) is a potentially preventable cause of death in people with lung cancer. Identification of those most at risk and high-risk periods may provide the opportunity for ...

Venous thromboembolism is known to be a major preventable cause of morbidity and mortality worldwide.1 In order to reduce the morbidity and mortality associated with venous thromboembolism, it is ...

New meta-analysis finds oral anticoagulants reduce net adverse events in patients with atrial fibrillation after intracranial hemorrhage but with a higher risk for recurrent intracranial hemorrhage.

Background: Whether to continue oral anticoagulant therapy beyond 6 months after an “unprovoked” venous thromboembolism is controversial. We sought to determine clinical predictors to identify ...

The extended use of vitamin K antagonists for prophylaxis against venous thromboembolism is often constrained by risk–benefit limitations and inconvenience. We evaluated the efficacy and safety ...

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It ...

Venous thromboembolism occurs in 40 to 84 percent of patients who undergo total knee replacement and do not receive prophylactic drugs; in 9 to 20 percent of these patients the thrombosis is ...

The association between cancer and venous thromboembolism (VTE) is well established, 1,2 with highest risk in the first few months after diagnosis. 3 VTE risk is further increased by chemotherapy ...